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Discussion
Dr Robert C. Robbins (Stanford, Calif). You went through it very
quickly, but this is a tour de force; technically it is a very difficult
model and you are to be congratulated for getting the animals
through this. Also impressive is the sophisticated use of molecular
genetics that you used here to help answer important questions.
Certainly heart failure is an important public health issue. Finally,
the experimental therapeutic approach to try to identify potential
targets for developing small molecules or other strategies to treat
heart failure is impressive.
I have just a couple of comments and questions for you.
GATA-4 and NKx2.5 are things that we are looking at as
embryonic stem cells differentiate into cardiac myocytes. I thought
it was interesting that you targeted these particular transcription
factors. You mentioned the isoform shift of cardiac myosin in your
manuscript, and a lot of work has been done by Jeff Robbins in this
area. I would like to note that you mentioned cardiac myosin.
Because it is so important in allograft rejection and autoimmune
disease, can you comment on what you found with cardiac myosin
specifically?
Dr Azakie. We used the MF20 antibody, which selects for
myosins. The purpose of looking at changes in sarcomeric gene
expression was to show that, in fact, there was biochemical hy-
pertrophy. We did not look specifically for different myosin iso-
forms. What we wanted to show is that despite no change in DNA
content, there was an upregulation in myosin proteins. The purpose
in evaluating cTnT expression was to show that, in fact, an
embryonic gene expression pattern induced a marker of the devel-
opment of pathologic hypertrophy. We also looked at serum brain
natriuretic peptide and found that it was significantly upregulated
in shunted animals. We did not look at isoform-specific expression
of different myosins.
Dr Robbins. You hit on other things that I was going to ask
you about. Have you thought about using microarrays? I’ve been
impressed that often this is a fishing expedition, but it can often
direct you to other things. You have done it the old-fashioned way.
You have picked a couple of things and gone after them in the
classic sense. Have you thought about using microarrays to look
for other targets? We have recently discovered a gene termed
APLN in heart failure patients who had ventricular assist devices.
I wonder whether you could get more targets if you would con-
sidered using microarray techniques.
Dr Azakie. We thought about using microarrays, but there are
no good ovine arrays available now. They are in preparation. The
main issue that my colleagues and collaborators have had with that
approach is that it does not always necessarily provide a mecha-
nistic answer toward the switch to a hypertrophic program.
I think the main message here resided in the posttranslational
modifications and the functional assays that we performed. Neo-
natal ovine cardiomyocytes were cultured and cotransfected with
cardiac promoters and expression constructs that encoded different
transcription factors. We found that TEF-1 and Sp1 were transcrip-
tional activators, whereas Sp3 was a repressor. GATA-4 and
NKX2.5 were selected because they are very well-known tran-
scriptional activators that are important for development and really
set a standard.
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The next level was to look at the posttranslational modifications
that occurred, and specifically acetylation and ADP-ribosylation.
Cardiac histone acetylation has been implicated in pathologic
cardiac growth, and currently there are HDAC inhibitors that are
being developed for use in cancer therapy in ongoing clinical trials.
Class I HDAC inhibitors have recently been shown to suppress
the development of hypertrophy in a rodent model where the aorta
was banded or angiotensin was infused.
The answer to the question, in short, is that we were interested
in trying to determine the mechanisms by which the hypertrophic
transcriptional program was initiated and that is why we did not do
microarrays.
Dr Robbins. You mentioned in your manuscript about models
of pressure overload to the left ventricle that are much easier to do,
such as constriction of the ascending aorta in transgenic mice. This
is very specific to the previous point. You are to be congratulated
for focusing in and testing the specific hypothesis, but I wonder
whether this is too narrow an area. I understand that your interest
is in surgery for congenital heart disease, but how do you think that
these data would translate into more generalizable models of
ischemic cardiomyopathy or rapid pacing, other models of heart
failure?
Finally, how do you choose the next step? Do you try to block
Sp1 or do you try to increase Sp3 in pharmacologic methods?
Dr Azakie. This model is interesting because it mimics certain
congenital heart defects, but the model can be tailored to produce
pressure loading of the left ventricle.
With regard to other more common causes of congestive heart
failure, I think that our hypothesis, and the hypotheses of others, is
that although there are different types of biomechanical stressors,
like pressure overload, volume overload, and ischemia-reperfusion
injury, which stimulate different intracellular signaling pathways,
we believe that ultimately there is a transcriptional reprogramming
that develops within the nucleus of the cardiac myocyte and so
really represents a final common pathway.
Finally, with regard to the next step for this line of research,
I think our plan will be to use selective class I HDAC inhibitors
as well as selective HAT inhibitors in determining whether or
not those agents can either reverse the (volume-loaded) hyper-
trophic process or prevent the development of heart failure.
Dr Ludwig K. von Segesser (Lausanne, Switzerland). Did
you consider going the other way around and closing the shunt
to see how your molecular patterns precede or follow the
morphology?
Dr Azakie. That’s a very good question. We did not do that.
Maybe doing that would be an interesting way to support the
mechanisms that we are trying to infer here. It’s a very good
question and good suggestion. Thank you.
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